MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 591152 | Name: Adibendan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Adibendan is an inhibitor of phosphodiesterase III.

Chemical Structure

Adibendan
CAS#100510-33-6

Theoretical Analysis

MedKoo Cat#: 591152

Name: Adibendan

CAS#: 100510-33-6

Chemical Formula: C16H14N4O

Exact Mass: 278.1168

Molecular Weight: 278.32

Elemental Analysis: C, 69.05; H, 5.07; N, 20.13; O, 5.75

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Adibendan;
IUPAC/Chemical Name
Pyrrolo(2,3-f)benzimidazol-6(1H)-one, 5,7-dihydro-7,7-dimethyl-2-(4-pyridinyl)-
InChi Key
TVLQBBHUNDMTEC-UHFFFAOYSA-N
InChi Code
InChI=1S/C16H14N4O/c1-16(2)10-7-12-13(8-11(10)20-15(16)21)19-14(18-12)9-3-5-17-6-4-9/h3-8H,1-2H3,(H,18,19)(H,20,21)
SMILES Code
O=C(N1)C(C)(C)C2=C1C=C3N=C(C4=CC=NC=C4)NC3=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 278.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Schneider J, Beck E, Heers C, Conrad C, de Chaffoy de Courcelles D, Wilffert B, Peters T. Cardiac effects of R 79595 and its isomers (R 80122 and R 80123) in an acute heart failure model. A new class of cardiotonic agents with highly selective phosphodiesterase III inhibitory properties. Naunyn Schmiedebergs Arch Pharmacol. 1992 Nov;346(5):563-72. PubMed PMID: 1470228. 2: de Cheffoy de Courcelles D, de Loore K, Freyne E, Janssen PA. Inhibition of human cardiac cyclic AMP-phosphodiesterases by R 80122, a new selective cyclic AMP-phosphodiesterase III inhibitor: a comparison with other cardiotonic compounds. J Pharmacol Exp Ther. 1992 Oct;263(1):6-14. PubMed PMID: 1328613. 3: Murray KJ, England PJ. Inhibitors of cyclic nucleotide phosphodiesterases as therapeutic agents. Biochem Soc Trans. 1992 May;20(2):460-4. Review. PubMed PMID: 1327922. 4: Ling Y. [Research on a new type of cardiotonic agents with calcium-sensitizing activity]. Sheng Li Ke Xue Jin Zhan. 1992 Jan;23(1):41-5. Review. Chinese. PubMed PMID: 1329193. 5: Schmitz W, Eschenhagen T, Mende U, Müller FU, Neumann J, Scholz H. Phosphodiesterase inhibition and positive inotropy in failing human myocardium. Basic Res Cardiol. 1992;87 Suppl 1:65-71. PubMed PMID: 1323266. 6: Wilhelm D, Wilffert B, Janssens WJ, Leidig A, Meuter C, Ebbert M, Peters T. In vitro pharmacology of R 80122, a novel phosphodiesterase inhibitor. J Cardiovasc Pharmacol. 1992;20(5):705-14. PubMed PMID: 1280731. 7: von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, et al. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. PubMed PMID: 1723153. 8: Rauch B, Zimmermann R, Kapp M, Haass M, Von Molitor S, Smolarz A, Neumann FJ, Kübler W, Dietz R, Tillmanns H. Hemodynamic and neuroendocrine response to acute administration of the phosphodiesterase inhibitor BM14.478 in patients with congestive heart failure. Clin Cardiol. 1991 May;14(5):386-95. PubMed PMID: 2049889. 9: Dorszewski A, Müller-Beckmann B, Kling L, Sponer G. Haemodynamic profile of an inhibitor of phosphodiesterase III, adibendan (BM 14.478): comparison with nitroprusside and dobutamine in conscious dogs. Br J Pharmacol. 1990 Nov;101(3):686-90. PubMed PMID: 2076485; PubMed Central PMCID: PMC1917742. 10: Peters P, Saborowski F, May E, Schneider M. [Central hemodynamics of a new positive inotropic substance, adibendan. Data from a dose-finding study]. Arzneimittelforschung. 1990 Jun;40(6):666-8. German. PubMed PMID: 2397002. 11: Kitada Y, Morita M, Narimatsu A. Comparison of the effects of MCI-154, a new cardiotonic agent, and some Ca2+-sensitizing agents on the response of the contractile system to Ca2+ in skinned cardiac muscle. Jpn J Pharmacol. 1989 Aug;50(4):411-9. PubMed PMID: 2789299. 12: Voelker W, Mauser M, Preisack M, Karsch KR. Acute hemodynamic effects of adibendan, a new phosphodiesterase inhibitor, for severe congestive heart failure. Am J Cardiol. 1989 Aug 1;64(5):390-2. PubMed PMID: 2756885. 13: von der Saal W, Hölck JP, Kampe W, Mertens A, Müller-Beckmann B. Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles. J Med Chem. 1989 Jul;32(7):1481-91. PubMed PMID: 2544724. 14: Neubert P, Hölck JP. Automated pre-column high-performance liquid chromatographic method for the investigation of adibendan metabolism. J Chromatogr. 1989 May 5;490(1):155-64. PubMed PMID: 2760147. 15: Rüegg JC, Morano I. Calcium-sensitivity modulation of cardiac myofibrillar proteins. J Cardiovasc Pharmacol. 1989;14 Suppl 3:S20-3. PubMed PMID: 2478799. 16: Bethke T, Brunkhorst D, von der Leyen H, Meyer W, Nigbur R, Scholz H. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14.478), in guinea-pig hearts. Naunyn Schmiedebergs Arch Pharmacol. 1988 May;337(5):576-82. PubMed PMID: 2457816. 17: Müller-Beckmann B, Freund P, Honerjäger P, Kling L, Rüegg JC. In vitro investigations on a new positive inotropic and vasodilating agent (BM 14.478) that increases myocardial cyclic AMP content and myofibrillar calcium sensitivity. J Cardiovasc Pharmacol. 1988 Jan;11(1):8-16. PubMed PMID: 2450261. 18: Müller-Beckmann B, Sponer G, Strein K, Bartsch W. Hemodynamic profile of BM 14.478: a new positive inotropic and vasodilating agent. J Cardiovasc Pharmacol. 1988 Jan;11(1):1-7. PubMed PMID: 2450246. 19: Reiff K. High-performance liquid chromatographic method for the determination of adibendan in plasma and urine. J Chromatogr. 1987 Nov 27;422:346-52. PubMed PMID: 3437024. 20: Freund P, Müller-Beckmann B, Strein K, Kling L, Rüegg JC. Ca2+-sensitizing effect of BM 14.478 on skinned cardiac muscle fibres of guinea-pig papillary muscle. Eur J Pharmacol. 1987 Apr 14;136(2):243-6. PubMed PMID: 3595723.

View History

SGC2085 free base

SGC2085 free base

New Featured